Although the response rate improved in the anti-CD38 treated MM cohort (Figure 2D, from 12 to 15 of 17 patients), the booster vaccination did not improve the response rate in the WM on-therapy (Figure 2B) and MM cohorts on anti-BCMA therapy (Figure 2E). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.